SAN DIEGO, April 22, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present updated Phase 2 results of spevatamig (PT886) in combination with chemotherapy…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
